VectivBio to be Acquired by Ironwood
Basel, Switzerland – May 23, 2023 – Cooley advised VectivBio, a clinical-stage biotech company focused on the discovery and development of treatments for severe, rare gastrointestinal (GI) conditions, on its acquisition by Ironwood, with an estimated aggregate consideration of approximately $1 billion. The deal was structured in a precedent-setting, all-cash tender offer for the Swiss Nasdaq-listed company. Partners Michal Berkner and Brandon Fenn led the Cooley team, along with associate Rita Sobral.
The acquisition of VectivBio and its lead investigational asset apraglutide provides a significant opportunity to accelerate the next growth horizon for Ironwood. The transaction has the potential to strengthen Ironwood’s innovative portfolio and pipeline to advance treatment for GI diseases and redefine the standard of care for GI patients.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.